



YEMEN

Number of new cases

16 525

Number of deaths


11 854

Number of prevalent cases (5-year)

31 811


Statistics at a glance, 2022

	Males	Females	Both sexes
Population	15 690 895	15 463 971	31 154 866
Incidence*			
Number of new cancer cases	7 213	9 312	16 525
Age-standardized incidence rate	77.8	89.2	83.1
Risk of developing cancer before the age of 75 years (cum. risk %)	8.0	8.8	8.4
Top 3 leading cancers (ranked by cases)**	Colorectum Stomach NHL	Breast Colorectum Oesophagus	Breast Colorectum Leukaemia
Mortality*			
Number of cancer deaths	5 515	6 339	11 854
Age-standardized mortality rate	63.8	64.5	63.7
Risk of dying from cancer before the age of 75 years (cum. risk %)	6.7	6.7	6.7
Top 3 leading cancers (ranked by deaths)**	Colorectum Stomach Liver	Breast Colorectum Oesophagus	Breast Colorectum Leukaemia
Prevalence*			
5-year prevalent cases	13 588	18 223	31 811



Top 5 most frequent cancers**

Males




Total: 7 213

Rank	Cancer site	Number of cases	Percent
1st	Colorectum	832	11.5%
2nd	Stomach	521	7.2%
3rd	NHL	506	7.0%
4th	Leukaemia	502	7.0%
5th	Liver	461	6.4%
-	Others	4 391	60.9%

Number of new cases in 2022, males, all ages

Females




Total: 9 312

Rank	Cancer site	Number of cases	Percent
1st	Breast	2 872	30.8%
2nd	Colorectum	740	7.9%
3rd	Oesophagus	529	5.7%
4th	Leukaemia	505	5.4%
5th	Stomach	411	4.4%
-	Others	4 255	45.7%

Number of new cases in 2022, females, all ages

Both sexes



Total: 16 525

Rank	Cancer site	Number of cases	Percent
1st	Breast	2 872	17.4%
2nd	Colorectum	1 572	9.5%
3rd	Leukaemia	1 007	6.1%
4th	Stomach	932	5.6%
5th	Oesophagus	858	5.2%
-	Others	9 284	56.2%

Number of new cases in 2022, both sexes, all ages

Incidence, Mortality and Prevalence by cancer site

Cancer	New cases				Deaths				5-year prevalence	
	Number	Rank	(%)	Cum.risk	Number	Rank	(%)	Cum.risk	Number	Prop. (per 100 000)
Breast	2 872	1	17.4	2.5	1 528	1	12.9	1.4	5 930	38.4
Colorectum	1 572	2	9.5	1.0	1 062	2	9.0	0.70	2 937	9.4
Leukaemia	1 007	3	6.1	0.38	859	3	7.2	0.37	2 033	6.5
Stomach	932	4	5.6	0.67	814	4	6.9	0.60	1 475	4.7
Oesophagus	858	5	5.2	0.64	781	5	6.6	0.62	1 363	4.4
NHL	851	6	5.2	0.35	585	9	4.9	0.27	1 829	5.9
Lung	774	7	4.7	0.45	749	6	6.3	0.44	1 429	4.6
Brain CNS	757	8	4.6	0.27	604	8	5.1	0.25	1 765	5.7
Liver	726	9	4.4	0.51	694	7	5.9	0.49	1 108	3.6
Thyroid	526	10	3.2	0.22	139	18	1.2	0.09	1 157	3.7
Hodgkin lymphoma	411	11	2.5	0.16	197	16	1.7	0.10	951	3.1
Nasopharynx	387	12	2.3	0.14	299	10	2.5	0.12	881	2.8
Ovary	341	13	2.1	0.28	224	13	1.9	0.24	694	4.5
Pancreas	334	14	2.0	0.21	286	11	2.4	0.19	505	1.6
Bladder	333	15	2.0	0.23	211	14	1.8	0.16	694	2.2
Larynx	311	16	1.9	0.21	257	12	2.2	0.19	585	1.9
Lip, oral cavity	287	17	1.7	0.19	207	15	1.7	0.14	541	1.7
Cervix uteri	212	18	1.3	0.26	153	17	1.3	0.19	440	2.9
Salivary glands	174	19	1.1	0.10	114	20	0.96	0.08	372	1.2
Kidney	169	20	1.0	0.05	116	19	0.98	0.04	364	1.2
Prostate	160	21	0.97	0.27	111	21	0.94	0.16	230	1.5
Oropharynx	45	22	0.27	0.02	36	22	0.30	0.02	96	0.31
Vagina	36	23	0.22	0.05	28	23	0.24	0.04	59	0.38
Melanoma	34	24	0.21	0.02	19	24	0.16	0.01	77	0.25
Testis	28	25	0.17	0.02	12	26	0.10	0.01	67	0.43
Gallbladder	18	26	0.11	0.01	10	27	0.08	0.01	31	0.10
Vulva	18	26	0.11	0.02	10	27	0.08	0.01	28	0.18
Multiple myeloma	18	26	0.11	0.01	15	25	0.13	0.01	34	0.11
Corpus uteri	16	29	0.10	0.02	10	27	0.08	0.01	37	0.24
Hypopharynx	15	30	0.09	0.01	7	30	0.06	0.01	19	0.06
Kaposi sarcoma	13	31	0.08	0.01	6	31	0.05	0.00	15	0.05
Mesothelioma	2	32	0.01	0.00	2	32	0.02	0.00	4	0.01
All cancers	16 525	-	-	8.4	11 854	-	-	6.7	31 811	-
All cancers excl. NMSC	16 260	-	-	8.2	11 726	-	-	6.6	31 248	-

Data source and methods

Incidence

Country-specific data source: [{"dt_list": "Aden cancer registry"}, {"dt_list": "Hadramout cancer registry"}, {"dt_list": "Sanaa cancer registry"}]

Method: National (or sub-national with coverage greater than 50%) rates projected to 2022

[Click here to see detailed data source](#)

Mortality



Country-specific data source: No data

Method: Estimated from national incidence estimates by modelling, using mortality:incidence ratios derived from survival estimation

[Click here to see detailed data source and method](#)

Prevalence

Computed using sex-, site- and age-specific incidence to 1-,3- and 5-year prevalence ratios from Nordic countries for the period (2011-2020), and scaled using Human Development Index (HDI) ratios.



* includes non-melanoma skin cancer (NMSC)

** NMSC included in other cancers

Age standardization using world population ([see link](#))

References

Website citation

Ferlay J, Ervik M, Lam F, Laversanne M, Colombet M, Mery L, Piñeros M, Znaor A, Soerjomataram I, Bray F (2024). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Available from: <https://gco.iarc.who.int/today>, accessed [DD Month YYYY].

Cancer incidence and mortality data

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 Feb 4. doi: 10.3322/caac.21660. Epub ahead of print. PMID: 33538338.

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021 Apr 5. doi: 10.1002/ijc.33588. Epub ahead of print. PMID: 33818764.

